Sector News

Endo keeps up its Valeant act with asset-sale talks

June 29, 2016
Life sciences

No one has the Valeant act down quite like Endo. After a guidance-slashing reminiscent of the Canadian pharma’s, the Dublin drugmaker is now following up with asset-sale discussions.

Endo has held talks with private equity firms about potential divestments that could help cut down its $8 billion-plus mountain of debt, Reuters’ sources say. It’s been looking into several options, including an asset swap with another company–though discussions are still in the early stages.

Endo–whose CEO, Rajiv De Silva, previously served as the COO at Valeant–has long seemed to be following in the footsteps of its specialty pharma peer, piling up debt in its race to gobble up smaller companies.

But these days, that’s no longer a good thing. Valeant has gone from Wall Street darling to bottom-feeder as debt-default concerns and dismal sales have taken their toll, and its new CEO–Perrigo vet Joseph Papa–has touted potential asset sales as a way to pay down debt and reduce some of the complexity of Valeant’s business.

Endo, too, reported disappointing quarterly sales last month that forced it to lower its 2016 EPS and revenue benchmarks. Shareholders–as Valeant’s did after a similar takedown in March–bolted for the exits. Shares crashed by nearly 40% as management attributed the change to new rivals on the market, greater-than-expected generics price erosion and regulatory delays.

Now, it remains to be seen if asset sales can turn Endo’s performance around–though after last month’s events, some analysts may be hard to convince.

“Weak longer term outlook, drastically lowered guidance, and pushed out de-levering targets (4.6x leverage) are the key reasons we view the stock as toxic,” Mizuho analyst Irina Koffler wrote after the guidance adjustments, adding that she “can’t see a reason” to own Endo shares.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”